Malathion
Malathion (malathion) is a small molecule pharmaceutical. Malathion was first approved as Ovide on 1982-08-02. It is used to treat lice infestations in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Malathion (discontinued: Malathion, Ovide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Malathion
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OVIDE | Taro Pharmaceutical | N-018613 DISCN | 1982-08-02 | 1 products, RLD |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lice infestations | — | D010373 | B85.2 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lice infestations | D010373 | — | B85.2 | 1 | 3 | 6 | — | — | 9 |
| Pediculus | D010374 | — | — | — | 1 | 1 | — | — | 2 |
| Scabies | D012532 | — | B86 | — | — | 1 | — | — | 1 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Malathion |
| INN | — |
| Description | Diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate is a diester that is diethyl succinate in which position 2 is substituted by a (dimethoxyphosphorothioyl)thio group. It is a diester, an ethyl ester and an organic thiophosphate. It is functionally related to a diethyl 2-sulfanylbutanedioate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC |
Identifiers
| PDB | — |
| CAS-ID | 121-75-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200468 |
| ChEBI ID | 6651 |
| PubChem CID | 4004 |
| DrugBank | DB00772 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Malathion
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,584 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
156 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use